Renli Teng

4.2k total citations · 1 hit paper
63 papers, 3.3k citations indexed

About

Renli Teng is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Pharmacology. According to data from OpenAlex, Renli Teng has authored 63 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Cardiology and Cardiovascular Medicine, 19 papers in Surgery and 14 papers in Pharmacology. Recurrent topics in Renli Teng's work include Antiplatelet Therapy and Cardiovascular Diseases (41 papers), Lipoproteins and Cardiovascular Health (16 papers) and Venous Thromboembolism Diagnosis and Management (14 papers). Renli Teng is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (41 papers), Lipoproteins and Cardiovascular Health (16 papers) and Venous Thromboembolism Diagnosis and Management (14 papers). Renli Teng collaborates with scholars based in United States, United Kingdom and Sweden. Renli Teng's co-authors include Kathleen Butler, Robert F. Storey, Cheryl Wei, Udaya S. Tantry, Paul A. Gurbel, Kevin P. Bliden, Mark J. Antonino, Arun Karunakaran, Shankar B. Patil and Stuart Oliver and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and European Heart Journal.

In The Last Decade

Renli Teng

61 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease

2009 794 citations Paul A. Gurbel, Kevin P. Bliden et al. Circulation profile →

Peers

Countries citing papers authored by Renli Teng

Since Specialization

Citations

This map shows the geographic impact of Renli Teng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Renli Teng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Renli Teng more than expected).

Fields of papers citing papers by Renli Teng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Renli Teng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Renli Teng. The network helps show where Renli Teng may publish in the future.

Co-authorship network of co-authors of Renli Teng

This figure shows the co-authorship network connecting the top 25 collaborators of Renli Teng. A scholar is included among the top collaborators of Renli Teng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Renli Teng. Renli Teng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Bioavailability, Metabolism, and Excretion of [¹⁴C]‐Tazemetostat in Patients With B‐Cell Lymphomas or Advanced Solid Tumors	Clinical Pharmacology in Drug Development	Yingxue Chen, Renli Teng et al.	1
2	Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function	European Journal of Clinical Pharmacology	Renli Teng, Yonggang Zhao et al.	6
3	Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI	Journal of the American College of Cardiology	Dominick J. Angiolillo, Francesco Franchi et al.	35
4	Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update	Clinical Pharmacokinetics	Renli Teng	112
5	TICAGRELOR VERSUS CLOPIDOGREL IN AFRICAN AMERICAN PATIENTS WITH CORONARY ARTERY DISEASE AND DIABETES MELLITUS	Journal of the American College of Cardiology	Ron Waksman, Juan Maya et al.	2
6	Evaluation of the Pharmacokinetic Interaction Between Ticagrelor and Venlafaxine, a Cytochrome P-450 2D6 Substrate, in Healthy Subjects	Clinical Therapeutics	Renli Teng, Judith Hsia et al.	7
7	Pharmacokinetic Interaction Study of Ticagrelor and Cyclosporine in Healthy Volunteers	Clinical Drug Investigation	Renli Teng, Judith Hsia et al.	18
8	Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers	PubMed	Renli Teng, Kathleen Butler	40
9	Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers	European Journal of Clinical Pharmacology	Renli Teng, Pat Mitchell et al.	53
10	Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers	Platelets	Renli Teng, Juan Maya et al.	35
11	Incidence of Dyspnea and Assessment of Cardiac and Pulmonary Function in Patients With Stable Coronary Artery Disease Receiving Ticagrelor, Clopidogrel, or Placebo in the ONSET/OFFSET Study	Journal of the American College of Cardiology	Robert F. Storey, Kevin P. Bliden et al.	133
12	Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age	Journal of Hypertension	Franz Schaefer, Johan Van de Walle et al.	47
13	Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects	European Journal of Clinical Pharmacology	Renli Teng, Kathleen Butler	162
14	Abstract 5901: The Effect of Ticagrelor in Stable Coronary Artery Disease Patients Nonresponsive to Clopidogrel: The RESPOND Study	Circulation	Paul A. Gurbel, Kevin P. Bliden et al.	3
15	The Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor, Are Unaffected by a Single Dose of Alcohol	The Journal of Clinical Pharmacology	Troy C. Sarich, Susanne Johansson et al.	24
16	A Pharmacokinetic Study of the Combined Administration of Amiodarone and Ximelagatran, an Oral Direct Thrombin Inhibitor	The Journal of Clinical Pharmacology	Renli Teng, Troy C. Sarich et al.	17
17	The bioavailability of nasogastric versus tablet-form oral trovafloxacin in healthy subjects	The American Journal of Surgery	John Vincent, Renli Teng et al.	12
18	The pharmacokinetic effects of coadministration of morphine and trovafloxacin in healthy subjects	The American Journal of Surgery	John Vincent, Thomas A. Hunt et al.	14
19	Determination of trovafloxacin, a new quinolone antibiotic, in biological samples by reversed-phase high-performance liquid chromatography	Journal of Chromatography B Biomedical Sciences and Applications	Renli Teng, Thomas G. Tensfeldt et al.	46
20	Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers	Journal of Antimicrobial Chemotherapy	Renli Teng, Theodore E. Liston et al.	63

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact